Choon Yong Loo Buys Handful Of Shares In Raffles Medical Group
Choon Yong Loo Buys Handful Of Shares In Raffles Medical Group
Those following along with Raffles Medical Group Ltd (SGX:BSL) will no doubt be intrigued by the recent purchase of shares by Choon Yong Loo, Executive Chairman & CEO of the company, who spent a stonking S$1.5m on stock at an average price of S$0.89. While that only increased their holding size by 0.7%, it is still a big swing by our standards.
跟隨着新加坡交易所上市的萊佛士醫療集團有限公司(SGX:BSL)的股東無疑會對該公司的執行主席兼首席執行官Choon Yong Loo最近花費了150萬新加坡元以0.89新加坡元的平均價格買入股票的行爲着迷。儘管這僅僅增加了他們持有的股份0.7%,但從我們的標準來看,這仍然是一個很大的波動。
Raffles Medical Group Insider Transactions Over The Last Year
在過去一年裏,萊佛士醫療集團的內部交易情況
Notably, that recent purchase by Executive Chairman & CEO Choon Yong Loo was not the only time they bought Raffles Medical Group shares this year. Earlier in the year, they paid S$1.03 per share in a S$3.6m purchase. That means that an insider was happy to buy shares at above the current price of S$0.91. It's very possible they regret the purchase, but it's more likely they are bullish about the company. To us, it's very important to consider the price insiders pay for shares. As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. Choon Yong Loo was the only individual insider to buy shares in the last twelve months.
值得注意的是,萊佛士醫療集團執行主席兼首席執行官Choon Yong Loo最近購買公司股票並不是他們今年第一次購買萊佛士醫療集團股票。今年早些時候,他們以每股1.03新加坡元的價格進行了一筆360萬新加坡元的交易。 這意味着內部人士願意以上於當前0.91新加坡元的價格購買股票。 他們很有可能後悔這次購買,但更可能是他們對公司持看好態度。 對於我們來說,考慮內部人士購買股票的價格非常重要。 一般規則是,當內部人士以高於當前價格購買股票時,我們對股票感到更加樂觀,因爲這表明他們認爲該股票的價值很好,即使價格更高。Choon Yong Loo是過去十二個月內唯一一個購買股票的個人內部人士。
Choon Yong Loo bought a total of 41.10m shares over the year at an average price of S$0.99. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
Choon Yong Loo在過去一年裏以0.99新加坡元的平均價格購買了4110萬股。 您可以在下面看到內部交易(由公司和個人進行)在過去12個月裏的可視化呈現。 如果單擊圖表,您可以看到所有個人交易,包括股價、個人和日期!
There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).
內部人士正在購買的股票是無數的。如果您喜歡投資於較少知名公司,您可以查看此免費的公司列表(提示:內部人士一直在購買它們)。
Insider Ownership
內部人員持股情況
For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. It's great to see that Raffles Medical Group insiders own 15% of the company, worth about S$253m. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.
對於普通股東來說,值得查看公司內部人士持有多少股份。高比例的內部人士持股往往使公司領導更加關注股東利益。很高興看到萊佛士醫療集團的內部人士擁有公司15%的股份,價值約25300萬新元。大多數股東會很高興看到這種內部持股,因爲這表明管理層的激勵與其他股東的利益高度一致。
So What Do The Raffles Medical Group Insider Transactions Indicate?
那麼萊佛士醫療集團內部交易究竟暗示了什麼?
It's certainly positive to see the recent insider purchase. And the longer term insider transactions also give us confidence. When combined with notable insider ownership, these factors suggest Raffles Medical Group insiders are well aligned, and quite possibly think the share price is too low. One for the watchlist, at least! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Raffles Medical Group. To assist with this, we've discovered 1 warning sign that you should run your eye over to get a better picture of Raffles Medical Group.
最近的內部人士購買情況無疑是積極的。長期內部交易也給我們帶來信心。當結合顯著的內部持股時,這些因素表明萊佛士醫療集團的內部人士利益是一致的,很可能認爲股價過低。至少可以將其列入自選股名單!除了了解正在進行的內部交易,識別萊佛士醫療集團面臨的風險也是有益的。爲了幫助您,我們發現了1個警示信號,建議您仔細審視,以更好地了解萊佛士醫療集團。
Of course Raffles Medical Group may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
當然,萊佛士醫療集團可能不是最適合買入的股票。因此,您可能希望查看這些高質量公司的免費收藏。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
譯文內容由第三人軟體翻譯。